Cure My Disease

Don't miss your cure!

 Log in / Sign up

500 patients to be tracked for long-term safety of cancer cell therapy

NCT ID NCT06785818

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study follows 500 people in South Korea who have received tisagenlecleucel, a CAR-T cell therapy, for certain blood cancers like acute lymphoblastic leukemia and lymphomas. Researchers will monitor side effects, risk of new cancers, and how well the treatment works over time. The goal is to understand the therapy's long-term safety in routine medical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma diffuse large B-cell lymphoma follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seongnam-si, Gyeonggi-do, 463-712, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gyeonggi-do, Korea, 10408, South Korea

  • Novartis Investigative Site

    RECRUITING

    Incheon, Korea, 405 760, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 02841, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 03312, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 08308, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 150-713, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Yangcheon gu, 07985, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 49201, South Korea

  • Novartis Investigative Site

    RECRUITING

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 04401, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    RECRUITING

    Ulsan, 44033, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.